Novocure [NVCR] vs Stryker [SYK] Detailed Stock Comparison

Novocure Ltd.

NASDAQ
Loading...

Stryker Corporation

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Novocure Ltd. wins in 8 metrics, Stryker Corporation wins in 11 metrics, with 0 ties. Stryker Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Novocure Ltd. Stryker Corporation Better
P/E Ratio (TTM) -10.32 39.21 Stryker Corporation
Price-to-Book Ratio 4.04 5.62 Novocure Ltd.
Debt-to-Equity Ratio 72.95 72.97 Novocure Ltd.
PEG Ratio 0.16 0.72 Novocure Ltd.
EV/EBITDA -8.82 19.90 Stryker Corporation
Profit Margin (TTM) -20.79% 12.92% Stryker Corporation
Operating Margin (TTM) -21.33% 27.24% Stryker Corporation
EBITDA Margin (TTM) N/A 27.24% N/A
Return on Equity -38.89% 15.08% Stryker Corporation
Return on Assets (TTM) -9.06% 7.92% Stryker Corporation
Free Cash Flow (TTM) $-75.68M $4.28B Stryker Corporation
Dividend Yield N/A 0.97% N/A
1-Year Return 1.31% -17.25% Novocure Ltd.
Price-to-Sales Ratio (TTM) 2.16 5.02 Novocure Ltd.
Enterprise Value $1.19B $138.30B Stryker Corporation
EV/Revenue Ratio 1.82 5.51 Novocure Ltd.
Gross Profit Margin (TTM) 75.82% 64.54% Novocure Ltd.
Revenue per Share (TTM) $6 $66 Stryker Corporation
Earnings per Share (Diluted) $-1.22 $8.40 Stryker Corporation
Beta (Stock Volatility) 0.82 0.93 Novocure Ltd.
Short % of Float 12.45% 1.20% Stryker Corporation

Novocure Ltd. vs Stryker Corporation Stock Performance Analysis

Loading Price Chart...

NVCR
SYK

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Novocure Ltd.-1.01%4.45%0.11%42.16%35.70%34.15%
Stryker Corporation-1.36%2.13%0.38%-11.91%-13.33%-11.56%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Novocure Ltd.1.31%-59.78%-91.85%63.27%-2.74%-2.74%
Stryker Corporation-17.25%6.06%22.47%172.95%440.98%592.85%

Performance & Financial Health Analysis: Novocure Ltd. vs Stryker Corporation

MetricNVCRSYK
Market Information
Market Cap i$1.46B$126.25B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i1,138,7621,881,406
90 Day Avg. Volume i1,141,0142,161,139
Last Close$17.60$307.94
52 Week Range$9.82 - $18.92$281.00 - $404.87
% from 52W High-6.98%-23.94%
All-Time High$232.76 (Jun 21, 2021)$406.19 (Jan 27, 2025)
% from All-Time High-92.44%-24.19%
Growth Metrics
Quarterly Revenue Growth0.08%0.11%
Quarterly Earnings Growth0.08%0.56%
Financial Health
Profit Margin (TTM) i-0.21%0.13%
Operating Margin (TTM) i-0.21%0.27%
Return on Equity (TTM) i-0.39%0.15%
Debt to Equity (MRQ) i72.9572.97
Cash & Liquidity
Book Value per Share (MRQ)$3.03$58.61
Cash per Share (MRQ)$3.93$10.71
Operating Cash Flow (TTM) i$-49,031,000$5.04B
Levered Free Cash Flow (TTM) i$-37,975,376$4.17B
Dividends
Last 12-Month Dividend Yield iN/A0.97%
Last 12-Month Dividend iN/A$3.40

Valuation & Enterprise Metrics Analysis: Novocure Ltd. vs Stryker Corporation

MetricNVCR (Apr 24, 2026)SYK (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-10.3239.21
Forward P/E i-10.4919.67
PEG Ratio i0.160.72
Price to Sales (TTM) i2.165.02
Price to Book (MRQ) i4.045.62
Market Capitalization
Market Capitalization i$1.46B$126.25B
Enterprise Value i$1.19B$138.30B
Enterprise Value Metrics
Enterprise to Revenue i1.825.51
Enterprise to EBITDA i-8.8219.90
Risk & Other Metrics
Beta i0.820.93
Book Value per Share (MRQ) i$3.03$58.61

Financial Statements Comparison: Novocure Ltd. vs Stryker Corporation

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNVCR (2025)SYK (2025)
Revenue/Sales i655.35M25.12B
Cost of Goods Sold i166.88M9.05B
COGS % of Revenue i25.5%36.0%
Gross Profit i488.47M16.07B
Gross Margin i74.5%64.0%
Research & Development i224.54M1.62B
Operating Income (EBIT) i-153.80M5.06B
Operating Margin i-23.5%20.1%
EBITDA i-100.24M6.48B
EBITDA Margin i-15.3%25.8%
Pre-Tax Income i-136.25M4.51B
Pre-Tax Income % of Revenue i-20.8%18.0%
Income Tax i-23,0001.27B
Income Tax % of Revenue i0.0%5.0%
Net Income (Profit) i-136.23M3.25B
Profit Margin i-20.8%12.9%

Balance Sheet & Liquidity Metrics

MetricNVCR (2025)SYK (2025)
Cash & Equivalents i93.55M4.01B
Total Current Assets i646.73M14.76B
Total Current Assets % of Revenue i98.7%58.7%
Total Current Liabilities i223.23M7.79B
Total Current Liabilities % of Revenue i34.1%31.0%
Long-Term Debt i236.69M14.86B
Long-Term Debt % of Revenue i36.1%59.2%
Total Shareholders Equity i340.47M22.42B
Retained Earnings i-1.29B20.47B
Retained Earnings % of Revenue i-196.9%81.5%
Property, Plant & Equipment i115.82M1.79B

Cash Flow Statement Comparison

MetricNVCR (2025)SYK (2025)
Operating Cash Flow i-50.83M4.70B
Operating Cash Flow % of Revenue i-7.8%18.7%
Capital Expenditures i-26.65M-761.00M
Free Cash Flow i-75.68M4.28B
FCF Margin i-11.5%17.1%
Debt Repayment i-560.95M-1.40B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricNVCRSYK
Shares Short i9.06M4.42M
Short Ratio i6.781.95
Short % of Float i12.45%1.20%
Shares Outstanding i112.49M382.50M
Float Shares i94.63M346.55M
% Held by Insiders i9.32%5.37%
% Held by Institutions i85.24%82.09%
% Held by Public i5.44%12.54%

Dividend Analysis & Yield Comparison: Novocure Ltd. vs Stryker Corporation

MetricNVCRSYK
Last 12-Month Dividend iN/A$3.40
Last 12-Month Dividend Yield iN/A0.97%
3-Year Avg Annual Dividend iN/A$3.23
3-Year Avg Dividend Yield iN/A0.24%
3-Year Total Dividends iN/A$9.69
Ex-Dividend DateN/ADec 31, 2025